The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 25, 2025

Filed:

May. 24, 2022
Applicant:

N.v. Nutricia, Zoetermeer, NL;

Inventors:

Patrick Joseph Gerardus Hendrikus Kamphuis, Utrecht, NL;

Martine Groenendijk, Barendrecht, NL;

Anke Bongers, Veenendaal, NL;

Assignee:

N.V. Nutricia, Zoetermeer, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/202 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A23L 33/12 (2016.01); A23L 33/15 (2016.01); A23L 33/16 (2016.01); A61K 31/14 (2006.01); A61K 31/557 (2006.01); A61K 31/7072 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/202 (2013.01); A23L 33/10 (2016.08); A23L 33/12 (2016.08); A23L 33/15 (2016.08); A23L 33/16 (2016.08); A23L 33/40 (2016.08); A61K 31/14 (2013.01); A61K 31/557 (2013.01); A61K 31/7072 (2013.01); A61K 45/06 (2013.01); A61P 25/28 (2018.01); A23V 2002/00 (2013.01);
Abstract

The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.


Find Patent Forward Citations

Loading…